Physician
Britton Kuzel, Catherine
Britton Kuzel, Catherine was paid $1.74M by Medicaid between Jan 2018 and Nov 2024, across 137 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 12% of everything it billed.
33Billing provider infoBRITTON KUZEL, CATHERINE
ELGIN, IL 60123
ELGIN, IL 60123
33aNPI1700918406assigned 03/09/2007
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$1.74M
24GClaims292,090
24DCodes billed137
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#46 of 398
Median peer was paid$66K
This provider vs. median27×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 65,825 | $309K | |
| 2019 | 77,458 | $482K | |
| 2020 | 91,927 | $471K | |
| 2021 | 53,143 | $398K | |
| 2022 | 2,913 | $48K | |
| 2023 | 462 | $18K | |
| 2024incomplete | 362 | $17K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 12% | 40,134 | 28,273 | $201K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7.6% | 46,910 | 30,413 | $132K |
| 87631 | 6.9% | 2,513 | 2,362 | $121K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6.8% | 5,630 | 5,241 | $119K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 5.7% | 2,555 | 2,158 | $99K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.5% | 2,310 | 2,227 | $79K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.0% | 1,219 | 1,081 | $69K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.2% | 365 | 330 | $56K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.1% | 249 | 248 | $54K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.6% | 11,861 | 6,350 | $46K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 1,430 | 1,304 | $42K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.2% | 7,528 | 6,318 | $38K |
125 more codes
| 87040 | 2.0% | 2,934 | $35K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.0% | 4,009 | $35K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 1,244 | $30K |
| 85027 | 1.7% | 10,657 | $29K | |
| 81001 | 1.6% | 20,237 | $28K | |
| 87641 | 1.6% | 1,235 | $27K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 3,147 | $25K |
| 81025 | 1.2% | 12,683 | $21K | |
| 88342 | 1.2% | 923 | $20K | |
| 83735 | 1.1% | 5,707 | $19K | |
| 84484 | 1.1% | 4,195 | $19K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 251 | $19K |
| 83690 | <1% | 4,656 | $16K | |
| 80061 | Lipid panel | <1% | 5,281 | $16K |
| 86901 | <1% | 5,517 | $13K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,475 | $12K |
| 86850 | <1% | 4,110 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 579 | $12K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 544 | $12K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 544 | $12K |
| 83880 | <1% | 1,165 | $11K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,615 | $11K |
| 84703 | <1% | 3,141 | $11K | |
| 88312 | <1% | 421 | $11K | |
| 85379 | <1% | 2,922 | $11K | |
| 81003 | <1% | 9,758 | $11K | |
| 86900 | <1% | 5,523 | $10K | |
| 82803 | <1% | 1,211 | $10K | |
| 86780 | <1% | 1,032 | $9K | |
| 85610 | <1% | 4,539 | $9K | |
| 82805 | <1% | 585 | $8K | |
| 82728 | <1% | 2,048 | $8K | |
| 87581 | <1% | 361 | $7K | |
| 82553 | <1% | 2,056 | $7K | |
| 87486 | <1% | 352 | $7K | |
| 83605 | <1% | 1,425 | $7K | |
| 85730 | <1% | 2,077 | $7K | |
| 86140 | <1% | 2,584 | $6K | |
| 87905 | <1% | 1,161 | $6K | |
| 84100 | <1% | 2,969 | $5K | |
| 83540 | <1% | 1,608 | $5K | |
| 87070 | <1% | 1,704 | $5K | |
| 87186 | <1% | 726 | $4K | |
| 87088 | <1% | 764 | $4K | |
| 87081 | <1% | 1,377 | $4K | |
| 85007 | <1% | 2,447 | $4K | |
| 82077 | <1% | 387 | $4K | |
| 80076 | <1% | 1,141 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 603 | $4K |
| 82962 | <1% | 1,758 | $3K | |
| 87205 | <1% | 1,810 | $3K | |
| 80069 | <1% | 821 | $3K | |
| 82550 | <1% | 1,021 | $3K | |
| 82140 | <1% | 714 | $3K | |
| 80143 | <1% | 208 | $2K | |
| 84439 | <1% | 544 | $2K | |
| 80179 | <1% | 202 | $2K | |
| 85652 | <1% | 1,703 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 89 | $2K |
| 84550 | <1% | 970 | $2K | |
| 80074 | <1% | 93 | $2K | |
| 80164 | <1% | 335 | $1K | |
| 83550 | <1% | 352 | $1K | |
| 82607 | <1% | 235 | $1K | |
| 84153 | <1% | 208 | $1K | |
| 84112 | <1% | 34 | $1K | |
| 82950 | <1% | 574 | $1K | |
| 87045 | <1% | 199 | $1K | |
| 82043 | <1% | 589 | $1K | |
| 88307 | <1% | 12 | $1K | |
| 86920 | <1% | 225 | $1K | |
| 87077 | <1% | 333 | $1K | |
| 84702 | <1% | 232 | $1K | |
| 83498 | <1% | 123 | $1K | |
| 82261 | <1% | 117 | $965.25 | |
| 83615 | <1% | 386 | $868.95 | |
| 82746 | <1% | 142 | $814.52 | |
| 83789 | <1% | 113 | $780.84 | |
| 82570 | <1% | 315 | $779.79 | |
| 86696 | <1% | 53 | $749.67 | |
| 83021 | <1% | 121 | $736.89 | |
| 87493 | <1% | 33 | $733.12 | |
| 87807 | <1% | 138 | $729.50 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 24 | $715.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $712.98 |
| 82248 | <1% | 290 | $675.43 | |
| 83516 | <1% | 138 | $654.11 | |
| 87210 | <1% | 276 | $642.51 | |
| 84466 | <1% | 144 | $633.81 | |
| 88304 | <1% | 29 | $592.31 | |
| 82150 | <1% | 185 | $581.42 | |
| 85018 | <1% | 696 | $579.03 | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 21 | $576.05 |
| 86695 | <1% | 53 | $567.66 | |
| 85384 | <1% | 191 | $538.55 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 21 | $450.00 |
| 86880 | <1% | 154 | $449.72 | |
| 85014 | <1% | 488 | $427.73 | |
| 86762 | <1% | 88 | $425.74 | |
| 82776 | <1% | 117 | $411.84 | |
| 87046 | <1% | 201 | $328.19 | |
| 87075 | <1% | 49 | $289.99 | |
| 86769 | <1% | 13 | $275.49 | |
| 86803 | <1% | 30 | $262.28 | |
| 86038 | <1% | 33 | $260.70 | |
| 82947 | <1% | 121 | $239.35 | |
| 82010 | <1% | 99 | $216.49 | |
| 85045 | <1% | 158 | $186.02 | |
| 87209 | <1% | 23 | $171.59 | |
| 82747 | <1% | 18 | $125.26 | |
| 86431 | <1% | 33 | $117.96 | |
| 87340 | <1% | 17 | $115.77 | |
| 86308 | <1% | 43 | $102.78 | |
| 82565 | <1% | 38 | $88.54 | |
| 84300 | <1% | 34 | $75.94 | |
| 84481 | <1% | 14 | $67.74 | |
| 36416 | <1% | 110 | $41.17 | |
| 81002 | <1% | 31 | $40.02 | |
| 84156 | <1% | 32 | $35.65 | |
| 84132 | <1% | 25 | $33.75 | |
| 82247 | <1% | 14 | $32.62 | |
| 84145 | <1% | 66 | $27.22 | |
| 82272 | <1% | 16 | $19.32 | |
| G0452 | Molecular pathology procedure; physician interpretation and report | <1% | 617 | $3.68 |
| 80329 | 0% | 191 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.